Corvus Pharmaceuticals (CRVS) Operating Leases (2019 - 2026)

Corvus Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $406000.0 for Q1 2026.

• In Q1 2026, Operating Leases fell 51.32% year-over-year to $406000.0; the TTM figure through Mar 2026 stood at $406000.0 (down 51.32% YoY), while the FY2025 annual figure was $534000.0, down 43.01% from the prior year.
• Operating Leases was $406000.0 for Q1 2026 at Corvus Pharmaceuticals, down from $534000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $2.3 million in Q1 2022 to a low of $354000.0 in Q3 2023.
• Historically, Operating Leases has averaged $999823.5 across 5 years, with a median of $834000.0 in 2025.
• The sharpest annual moves came in 2022 and 2023: Operating Leases soared 216.8% in 2022, then slumped 79.04% in 2023.
• A 5-year view of Operating Leases shows it stood at $1.4 million in 2022, then rose by 0.07% to $1.4 million in 2023, then plunged by 31.8% to $937000.0 in 2024, then tumbled by 43.01% to $534000.0 in 2025, then decreased by 23.97% to $406000.0 in 2026.
• The last three Operating Leases figures came in at $406000.0 (Q1 2026), $534000.0 (Q4 2025), and $632000.0 (Q3 2025), per Business Quant data.